This study focused on the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) with motion-resolved compressed sensing T1-weighted volumetric interpolated breath-hold examination (CS-VIBE) for prediction of treatment response to chemotherapy and patient outcome in pancreatic ductal adenocarcinoma (PDAC). Our results showed tumor ve was significantly higher in the response group than in the non-response group and was an independent predictor of progression-free survival in patients with PDAC treated with chemotherapy. These results suggest that DCE-MRI obtained with CS-VIBE may be useful for predicting treatment response to chemotherapy and patient outcome in PDAC.
This abstract and the presentation materials are available to members only; a login is required.